News
Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback